Philippines Registration Certificate: Changing the Holder

1. Key takeaways

A Philippine registration certificate is registered in the name of the MAH and is bound to that entity. It cannot be transferred freely. Changing the holder requires an application to the FDA under the variation procedure, and the recognised preconditions are that the original agreement has been terminated, a new agreement has been signed, and the original certificate is in hand. The mechanism turns the choice of holder into the most consequential commercial decision an overseas manufacturer makes on entering the Philippine market.

The binding is not a drafting accident. It follows from the fact that the certificate is issued to the applicant, and the applicant is by definition the local entity that holds the LTO and carries the regulatory responsibility. Anything that changes the responsible party therefore changes the certificate, which is why a distributor dispute in the Philippines is never only a commercial dispute.

• The certificate is issued to the MAH and does not travel independently of that entity.
• Transfer is handled as a variation, with a fee and reissuance of the certificate.
• Three cumulative preconditions apply: termination of the old agreement, signature of the new one, and possession of the original certificate.
• The Philippines permits multiple registrations, so the same product can be registered separately by different MAHs.
• The cost of re-registration rises sharply once AO 2024-0016 is restored, since it is currently suspended.

2. Legal basis

Three administrative orders frame the position. AO No. 2018-0002 issues the certificate to the applicant. AO No. 2024-0015 limits the LTO to local entities, which is what makes the applicant local by construction. AO No. 2025-0030 states that the MAH is the responsible party for vigilance, which reinforces why the authority will not allow the certificate to float free of an accountable entity.

3. Expert insights

Insight one: the binding turns the certificate into a commercial asset held by the other side.

Because the certificate sits in the name of the MAH, the MAH holds the market access qualification for the product. Where the MAH is also the distributor, the manufacturer lacks leverage on price, territory and volume, since the counterparty controls the document that permits any sale at all. This problem exists across Southeast Asia, but it is sharper in the Philippines because multiple registration is permitted, so the same product can be registered separately by different MAHs. That looks flexible, and it is, but the flexibility is paid for by the manufacturer that wants to switch channels.

Insight two: the three preconditions are interlocking, not alternatives.

The transfer preconditions recognised in practice are termination of the original agreement, signature of the new agreement and possession of the original certificate. Missing any one of them stops the process. Possession of the original is the one most often overlooked: if the certificate is held by the outgoing holder and is not surrendered, the incoming holder has no key attachment for the variation application. We recommend writing the custody obligation for the original certificate and the unconditional duty to hand it over on termination directly into the holding agreement, so that the obligation exists before it is needed.

Insight three: multiple registration is the alternative route the Philippines offers.

Unlike some Southeast Asian markets, the Philippines allows the same product to be registered separately by different MAHs. A manufacturer can therefore have a new holder register the product afresh without confronting the incumbent. The price is a second set of official fees, a second technical file and a second waiting period. While fees are suspended the duplication is relatively manageable, but once AO 2024-0016 is restored to effect the cost of duplicate registration multiplies, and the economics of the alternative route change accordingly.

Insight four: the most robust solution is to choose the right holder at the outset.

Three structures are available: holding through an own subsidiary, which carries the highest cost and the strongest control; holding through the distributor, which carries the lowest cost and the highest risk; and holding through an independent third party, which balances the two. Where the product is a core line and the intention is to operate in the market for the long term, our position is that an own subsidiary or an independent third party is the better default. Placing the certificate with a distributor amounts to pledging market access to the channel.

4. Practical recommendations

• Lock the handover duty into the agreement stage. Provide that within a stated number of working days after termination the holder must unconditionally surrender the original certificate, the registration file, the original LOA and all technical documentation. The clause is worth little if it is negotiated after the relationship has broken down.
• Keep a complete copy of the registration file. The manufacturer should retain the full submission set and all correspondence with the FDA, so that a change of holder does not produce a documentary gap at the point where continuity has to be demonstrated.
• Compare the cost of re-registration against transfer. While the fee suspension is in force, re-registration is clearly more economical than accommodating an uncooperative incumbent. Once the suspension ends, negotiated transfer should be the preferred route, and the comparison should be rerun at that time rather than assumed.

5. Verification checklist

• □ Confirm the registered holder by checking the MAH name printed on the original certificate.
• □ Confirm termination of the original agreement with a termination agreement or notice letter from both parties.
• □ Confirm the new holding agreement and a new LOA, notarised and Apostilled.
• □ Confirm the validity of the incoming holder LTO through the FDA Verification Portal.
• □ Confirm physical possession of the original certificate.
• □ Confirm the variation fee and processing time applicable at the time of filing.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com